StocksMediumUpdated•Originally published 14 October 2026•Updated 14 October 2026•
1 min read
Verastem Oncology Prices Share Offering at $8.00 Amid CEO Transition
Key Facts
1Verastem Oncology announced a CEO transition and the pricing of a $250 million securities offering.
Verastem Oncology priced its common stock offering at $8.00 per share for the sale of 30,937,500 shares. The announcement comes alongside the appointment of Michael Bailey as the company's new president and CEO, effective January 1, 2027, according to Seeking Alpha.
VSTM closed at $7.45 on October 13, 2026, placing the newly announced offering price at a premium to the last closing level. The company had previously signaled a $250 million capital raise aimed at strengthening its balance sheet and supporting strategic growth initiatives under the incoming leadership.